ONLINEPORTAL FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE

Glossary A-Z



According to the NCI website Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health Link to National Cancer Institute Link zu Wiki

The IUPHAR/BPS Guide to PHARMACOLOGY